当前位置: 首页 >> 检索结果
2443. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
作者: Matthew J Frank.;John H Baird.;Anne Marijn Kramer.;Hrishikesh K Srinagesh.;Shabnum Patel.;Annie Kathleen Brown.;Jean S Oak.;Sheren F Younes.;Yasodha Natkunam.;Mark P Hamilton.;Yi-Jiun Su.;Neha Agarwal.;Harshini Chinnasamy.;Emily Egeler.;Sharon Mavroukakis.;Steven A Feldman.;Bita Sahaf.;Crystal L Mackall.;Lori Muffly.;David B Miklos.; .
来源: Lancet. 2024年404卷10450期353-363页
Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this study.
2445. Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial.
作者: R Michael Gendreau.;Lance M McCracken.;David A Williams.;Juan V Luciano.;Yifei Dai.;Nicolette Vega.;Zunera Ghalib.;Kristen Guthrie.;Allison C Kraus.;Michael J Rosenbluth.;Ben Vaughn.;Jennifer M Zomnir.;Dana Reddy.;Andrea L Chadwick.;Daniel J Clauw.;Lesley M Arnold.
来源: Lancet. 2024年404卷10450期364-374页
International guidelines have recommended cognitive behavioural therapy, including acceptance and commitment therapy (ACT), as it offers validated benefits for managing fibromyalgia; however, it is inaccessible to most patients. We aimed to evaluate the effect of a 12-week, self-guided, smartphone-delivered digital ACT programme on fibromyalgia management.
2453. Germany's role in global health at a critical juncture.
In 2017, we set out-along with a larger group of authors-to assess Germany's contribution and potential leadership role in global health. We considered the ambitions and manifold efforts of Chancellor Angela Merkel's administration to become a trusted leader in global health governance and a reliable supporter of multilateral institutions, especially WHO. Based on the recommendations of our 2017 paper, in this Review we determine whether the country has indeed lived up to its vision and ambitions expressed in the Global Health Strategy adopted by the cabinet in 2020. Also, we outline what challenges Germany is now facing in a more complex global health environment and geopolitical situation, where leadership in the field is being redefined following the impact of the COVID-19 pandemic and amid broader shifts in the international order.
|